Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3295668 + Midazolam |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3295668 | LY3295668 erbumine|AK-01 | Aurka Inhibitors 27 | LY3295668 selectively inhibits Aurora A kinase (AURA), which results in apoptosis, inhibition of cell proliferation, and tumor growth inhibition (PMID: 31530649). | |
Midazolam | Dormicum | Dea No. 2884 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03955939 | Phase I | LY3295668 + Midazolam LY3295668 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | Completed | USA | BEL | 0 |